Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than once drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus estramustine in
treating patients who have metastatic prostate cancer that has not responded to hormone
therapy.